EFFECTS OF A PRIOR AUTHORIZATION POLICY FOR CYCLOOXYGENASE-2 INHIBITORS ON HEALTH-RELATED OUTCOMES IN A MANAGED CARE MEDICAID POPULATION
Author(s)
Hartung DM, Touchette DR, Ketchum KL, Haxby DG, Oregon State University, Portland, OR, USA
OBJECTIVES: Prior authorization (PA) is a poorly studied, but commonly employed policy used by health care payers to manage the rising costs of pharmacy benefits. Our objective was to evaluate the impact of PA policies for cyclooxygenase-2 (COX-2) inhibitors on prescription drug and medical service utilization in a managed care Medicaid population. METHODS: The analysis was conducted from January 1, 1999 to October 31, 2001 when PA policies were enacted for celecoxib and rofecoxib. Monthly annualized rates of utilization were estimated using medical and prescription drug billing records. An autocorrelation-corrected segmented linear regression model was developed to evaluate trends in utilization temporally associated with PA initiation. The primary analysis evaluated utilization of related drug classes (e.g. conventional NSAIDs, PPIs), and office, emergency, and hospital encounters in all enrolled members. A secondary analysis was performed in a cohort of prior NSAID (conventional and COX-2) users. RESULTS: After each PA was activated, utilization of celecoxib and rofecoxib were immediately reduced from 1.07 to 0.53 days supply/person-year (58.9% reduction; 95% CI: 50.0%-67.9%) and 0.96 to 0.52 days supply/person-year (49.8% reduction; 95% CI: 40.5%-59.1%), respectively. Growth in utilization was slowed for both agents (p<0.0001). Utilization changes were not observed in other drug classes. Similar trends were observed in the secondary analysis. No changes in medical service use were noted with the exception of emergency room visits, which increased by 18.0% (95% CI: 2.2%-33.9%) and exhibited a higher growth rate after the PA for celecoxib was enacted. A similar, non-significant trend was observed in the secondary analysis. CONCLUSIONS: Utilization of rofecoxib and celecoxib was reduced substantially following the implementation of a PA policy. No important concomitant changes in the use of other drug classes were detected. The small increase in ER visits observed after the celecoxib PA was activated is a concerning finding that warrants further study.
Conference/Value in Health Info
2003-05, ISPOR 2003, Arlington, VA, USA
Value in Health, Vol. 6, No. 3 (May/June 2003)
Code
PAR2
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Musculoskeletal Disorders